Bone Abstracts

Recent studies confirmed the role of WNT16 in bone mineral density (BMD), bone strength and fracture risk. These findings made WNT16 interesting for further genetic and functional studies to clarify its effect on osteoporosis related parameters.A WNT16 candidate gene association study was performed in men from the Odense Androgen Study (OAS). Five tagSNPs and one multimarker test were selected for genotyping to cover most of th...

see PP404....

Growing body of evidence shows that microRNAs play an important role in regulating bone mass. We investigated the cooperative microRNA-mRNA regulatory mechanism of peak bone mass in inbred strain of mice with different bone density using microarray analysis. Femur and tibia of 12-week old C3H/He (high bone density) and C57BL/6 (low bone density) were harvested to extract total bone RNAs for microarray. A total of 30 miRNAs were differentially expressed between bone tissue of C...

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

A 20-year-old male presented following a fall down. He was diagnosed with a C5–C7 burst fracture and underwent a cervical fixation surgery. He was transferred to inpatient rehabilitation with C6 ASIA A tetraplegia.70 days after the operation, he began to have intermittent mild fever with a temperature of 37.4 oC. On postoperative day 72, left thigh was noted to be edematous. The circumferential difference between the lower extremities mea...

Objectives: We investigated bone mineral density (BMD) in women as this is related to a history of previous pregnancies and miscarriage and according to age.Materials and methods: We performed retrospective study on 1043 women who had their BMD in a university hospital. We analyzed the BMD and the previous obstetric history according to age and the clinical characteristics.Results: The mean age of the study subjects was 56.7±5...

Background: Adult GH Deficiency (GHD) is associated with decreased bone mass and increased fracture risk. Recombinant human GH (rhGH) replacement therapy leads to progressive increases in bone mineral density (BMD) for up to 7 years of treatment, but little is known on longer term effects of rhGH therapy on bone mass or fracture risk.Methods: 230 GHD patients (mean age 47.1 years, 52.6% female) on rhGH replacement therapy for ≥5 years were included...

Metabolic bone disease (MBD) of prematurity is a well-recognized complication of preterm birth. Yet there is limited evidence for the optimal assessment, monitoring, and subsequent bone health management.Retrospective audit of 171 infants born <32 weeks’ gestation between November 2012 and January 2014 at three Monash Health neonatal units (Melbourne, Australia) was undertaken. Infants had mean gestational age (GA) 28.6±2.1 weeks and birth ...

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...